PURPOSE: This prospective phase II study was designed to assess disease control and to describe acute and late adverse effects of treatment with proton radiotherapy in @entity1 with @entity980 ( @entity980 ). @entity1 AND METHODS: Fifty-seven @entity1 with localized @entity980 (age 21 years or younger) or metastatic embryonal @entity980 (age 2 to 10 years) were enrolled between February 2005 and August 2012. All @entity1 were treated with chemotherapy based on either @entity1891 , @entity4316 , and @entity786 or @entity1891 , @entity4316 , and @entity1260 -based chemotherapy and proton radiation. Surgical resection was based on @entity5 site and accessibility. Common Terminology Criteria for Adverse Events, Version 3.0, was used to assess and grade adverse effects of treatment. Concurrent enrollment onto @entity1 's Oncology Group or European @entity242 Study Group protocols was allowed. All pathology and imaging were reviewed at the treating institution. RESULTS: Median follow-up was 47 months (range, 14 to 102 months) for survivors. Five-year event-free survival (EFS), @entity1349 ( @entity1349 ), and local control (LC) were 69%, 78%, and 81%, respectively, for the entire cohort. The 5-year LC by risk group was 93% for low-risk and 77% for intermediate-risk disease. There were 13 @entity1 with grade 3 acute @entity137 and three @entity1 with grade 3 late @entity137 . There were no acute or late @entity137 higher than grade 3. CONCLUSION: Five-year LC, EFS, and @entity1349 rates were similar to those observed in comparable trials that used photon radiation. Acute and late @entity137 rates were favorable. Proton radiation appears to represent a safe and effective radiation modality for pediatric @entity980 .

Preliminary results of a phase II trial of proton radiotherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity242 :: ('MESH:D012509', 'Disease') :: ['Pediatric Sarcoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity4316 :: ('MESH:D003609', 'Chemical') :: ['actinomycin'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide'] @entity980 :: ('MESH:D012208', 'Disease') :: ['RMS', 'rhabdomyosarcoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity980 :: (MESH:D012208,Disease) :: ['pediatric rhabdomyosarcoma']
